Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700025 | 0.89 | LMNA (0.48) | LMNAMAPTPOLBBRD4ALDH1A1 | |
| SCHEMBL30467937 | 0.89 | LMNA (0.48) | LMNAMAPTPOLBBRD4ALDH1A1 | |
| SCHEMBL1700056 | 0.83 | LMNA (0.51) | LMNAMAPTPOLBBRD4ALDH1A1 | |
| SCHEMBL1699922 | 0.82 | BRD4 (0.45) | LMNAMAPTPOLBBRD4ALDH1A1 | |
| SCHEMBL1699921 | 0.82 | BRD4 (0.45) | LMNAMAPTPOLBBRD4ALDH1A1 | |
| SCHEMBL1700369 | 0.82 | BRD4 (0.45) | LMNAMAPTPOLBBRD4ALDH1A1 | |
| SCHEMBL1700380 | 0.82 | LMNA (0.42) | LMNAMAPTPOLBBRD4ALDH1A1 | |
| SCHEMBL1700651 | 0.82 | LMNA (0.47) | LMNAMAPTPOLBBRD4ALDH1A1 | |
| SCHEMBL1700850 | 0.82 | IKBKB (0.50) | LMNAMAPTPOLBBRD4ALDH1A1 | |
| SCHEMBL522841 | 0.82 | CA2 (0.48) | LMNAMAPTPOLBBRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | LMNA 2720/4885MAPT 3890/4885POLB 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.